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MANY attempts have been made to improve the results of radiotherapy in the
treatment of malignant disease. Mitchell (1942) found that therapeutic doses
of radiation inhibit the synthesis of thymonucleic acid in growing cells. He
considered that if a chemical agent could block the synthesis of nucleic acids in
the cells this substance in combination with radiotherapy may improve the
results of treatment. Experiments with tetra-sodium 2 methyl-I: 4-naptho-
hydroquinone diphosphate (Synthetic vitamin K or Synkavit) produced an
inhibition of mitosis in chick fibroblast cultures and in some human carcinomata.
In tissue cultures a potentiation of the effects of the X-radiation was found.
Since this report Mitchell and his colleagues have carried out a considerable
number of investigations on biological material (Mitchell, 1953, 1954; Mitchell
and Simon-Reuss, 1952; Hughes and Simon-Reuss, 1953). These investiga-
tions have confirmed their original findings. Similar observations of the effect
of Synkavit on cell division in chick and amphibian embryos were also made by
Bellairs (1954). Gellhorn and Gagliano (1950), however, investigated the effects
of Synkavit on mouse tumours and found that there was no significant difference
between the tumour weights of control and Synkavit groups. They concluded
" in the absence of any demonstrable carcinolytic or carcinostatic activity against
experimental neoplasms the applications of Synkavit alone in the therapy of
human cancer would appear to be questionable." The results of clinical trials
with this compound were first reported by Mitchell in 1948. Twenty-two patients
with a proved carcinoma ofthe bronchus were treated; 13 patients received deep-
X-ray therapy to the chest and the remaining 9 received X-ray therapy together
with an intramuscular injection of Synkavit.
Although the treatment of the two groups was not strictly comparable,
some received radical and some palliative X-ray therapy, it was shown that there
was an improvement in the mean survival time of the patients who received
Synkavit. The group having X-ray therapy alone survived for an average time
of 4-8 months while those patients receiving X-ray therapy and intramuscular
Synkavit survived for a mean time of 7-5 months. Mitchell concluded that the
administration of the compound produced a small but useful improvement in the
palliative results of X-ray therapy in some cases of carcinoma of the bronchus.
More recently Mitchell has shown an even further improvement in the survival
rate when the compound was given intravenously. The mean survival time for
a group of patients receiving radiotherapy alone was 4 months, for patients
receiving radiotherapy plus intramuscular Synkavit it was 6 months and for
patients receiving radiotherapy plus intravenous Synkavit it was 11 months
(Mitchell, 1954).T. J. DEELEY
Although Mitchell has shown a definite clinical improvement with Synkavit
there have been no other reports on the clinical use ofthis substance in the English
literature. This article describes a clinical trial to compare the results of treat-
ment in two groups of patients treated for carcinoma of the bronchus. The
first group received deep X-ray therapy to the chest and the second group received
similar deep X-ray therapy together with intravenous Synkavit. The patients
selected for the trial had a histologically proved anaplastic carcinoma of the
bronchus, had no evidence of spread outside the chest and had a tumour which
could be adequately covered by an X-ray field measuring 15 x 15 cm.
Although the treatment was palliative, only those patients who were thought
to have a reasonable expectation of life of at least one month were included.
Thirty-six patients were treated; 18 received X-ray therapy to the chest and
18 received similar X-ray therapy to the chest immediately after an intravenous
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FIG. 1.
injection of Synkavit. The two groups were treated at the same time and the
method of treatment was decided by random selection.
Treatment was given by two opposed fields to the chest, one anterior and one
posterior each measuring 15 x 15 cm. A tumour dose of 2500 roentgens was
given in 10 treatments. An intravenous injection of 200 mg. of Synkavit was
given while the patient was on the treatment couch about 5 min. before starting
each X-ray treatment. In the patients treated there were no complications which
could be attributed to the Synkavit although some patients did complain ofslight
pain and tightness in the chest immediately after the injection.
The survival rates ofthe two series are shown in the graph (Fig. 1). Although
there is very little difference in the 1 year survival rate of the two groups it will
be seen that at each month the cases treated by Synkavit and X-ray therapy show
a higher survival rate than do the cases treated by X-ray alone. The patients
receiving X-rays and Synkavit had an increased expectation of life of approxi-
mately 2-3 months.
DISCUSSION
In the design of a clinical trial of two different methods of treatment it is im-
portant that the two groups compared are exactly similar, the only variables
being the treatments under investigation.
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This trial was designed to test the effect of Synkavit as a chemical radiosensi-
tiser. Two similar groups of patients with carcinoma of the bronchus have been
treated. The composition of the two groups has been the same, all patients had
a proved carcinoma of the anaplastic type, the condition was considered to be
inoperable in all cases, there was no evidence ofspread ofdisease outside the chest
and all patients had a tumour which could be adequately covered with a 15 cm.
field. All the patients received the same X-ray tumour dose in the same period
of time. Half of the patients received, in addition, an intravenous injection of
Synkavit just before treatment.
The results suggest that Synkavit makes a small improvement in the X-ray
treatment of this disease and agrees with the findings made by Mitchell in his
clinical trials.
SUMMARY
A clinical trial of Synkavit in the treatment of carcinoma of the bronchus by
X-ray therapy is described. There was a small improvement in the survival
rates of those patients receiving the compound.
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